Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
NVAX - Novavax, Inc.
Market Cap 724.53M P/E - EPS this Y 81.70% Ern Qtrly Grth 179.90%
Income -294.33M Forward P/E -4.69 EPS next Y 72.70% 50D Avg Chg 7.00%
Sales 987.67M PEG -0.33 EPS past 5Y - 200D Avg Chg -23.00%
Dividend N/A Price/Book N/A EPS next 5Y 37.90% 52W High Chg -87.00%
Recommedations 2.50 Quick Ratio 0.93 Shares Outstanding 160.09M 52W Low Chg 50.00%
Insider Own 4.38% ROA -10.21% Shares Float 143.46M Beta 2.04
Inst Own 53.74% ROE - Shares Shorted/Prior 33.53M/30.50M Price 8.40
Gross Margin 16.18% Profit Margin -29.80% Avg. Volume 6,289,924 Target Price 20.00
Oper. Margin 39.01% Earnings Date Nov 7 Volume 6,171,024 Change -4.06%
Healthcare | Biotechnology | United States
About Novavax, Inc.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc. News
12/13/24 Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell In December 2024?
12/13/24 Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
12/12/24 Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report?
12/12/24 Institutional investors control 53% of Novavax, Inc. (NASDAQ:NVAX) and were rewarded last week after stock increased 6.3%
12/12/24 Sanofi’s combo vaccines gain FDA fast track designation
12/11/24 FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
12/11/24 NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
12/10/24 Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
12/10/24 Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
12/05/24 Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M
12/05/24 2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors
12/04/24 Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
12/04/24 Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 million
12/04/24 Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
11/29/24 Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
11/21/24 Matt Gaetz Withdraws. Why That Might Be Bad News for RFK.
11/18/24 Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
11/15/24 Pfizer, Moderna, BioNTech Take A Beating After Trump Taps Kennedy To Head Up HHS
11/15/24 Update: Moderna, Novavax, Pfizer Shares Fall on Nomination of Anti-Vaxxer as US Health Secretary
11/15/24 Trump looks to end EV credit, vaccine stocks fall on RFK JR. pick
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dubovsky Filip President, R&D President, R&D Dec 14 Option 5.69 2,833 16,120 55,150 12/18/23
Dubovsky Filip President, R&D President, R&D Nov 05 Option 7.06 1,400 9,884 52,994 11/07/23
Dubovsky Filip President, R&D President, R&D Sep 16 Option 7.71 12,644 97,485 57,702 09/19/23
Trizzino John EVP, CCO and CBO EVP, CCO and CBO Mar 10 Option 6.52 4,609 30,051 11,531 03/14/23
Kelly James Patrick EVP, CFO and Treasur.. EVP, CFO and Treasurer Mar 10 Option 6.52 4,609 30,051 5,832 03/14/23
Herrmann John A III EVP, Chief Legal Off.. EVP, Chief Legal Officer Mar 10 Option 6.52 4,609 30,051 13,058 03/14/23
Glenn Gregory M President, R&D President, R&D Mar 06 Buy 7.01 6,000 42,060 14,473 03/14/23
Glenn Gregory M President, R&D President, R&D Mar 06 Option 6.52 6,298 41,063 20,771 03/14/23
YOUNG JAMES F Director Director Mar 31 Sell 74.21 12,500 927,625 62,590 04/04/22
Herrmann John A III EVP, Chief Legal Off.. EVP, Chief Legal Officer Dec 01 Sell 197.3 5,000 986,500 2,760 12/03/21
Herrmann John A III EVP, Chief Legal Off.. EVP, Chief Legal Officer Dec 01 Option 19.08 5,000 95,400 7,760 12/03/21
Glenn Gregory M President, R&D President, R&D Nov 23 Option 19.08 8,250 157,410 12,311 11/24/21
Glenn Gregory M President, R&D President, R&D Nov 23 Sell 200.02 8,250 1,650,165 4,061 11/24/21
Glenn Gregory M President, R&D President, R&D Nov 02 Option 19.08 8,250 157,410 12,311 11/04/21
Glenn Gregory M President, R&D President, R&D Nov 02 Sell 186.83 8,250 1,541,348 4,061 11/04/21
Glenn Gregory M President, R&D President, R&D Oct 26 Option 10.33 11,712 120,985 5,439 10/28/21
Glenn Gregory M President, R&D President, R&D Oct 26 Sell 132.97 10,334 1,374,112 4,061 10/28/21
Glenn Gregory M President, R&D President, R&D Oct 19 Option 19.08 8,250 157,410 12,311 10/21/21
Glenn Gregory M President, R&D President, R&D Oct 19 Sell 166.54 8,250 1,373,955 4,061 10/21/21
Glenn Gregory M President, R&D President, R&D Oct 12 Option 19.08 8,250 157,410 12,311 10/14/21
Glenn Gregory M President, R&D President, R&D Oct 12 Sell 164.07 8,250 1,353,578 4,061 10/14/21
Glenn Gregory M President, R&D President, R&D Jun 17 Option 22.5 10,535 237,038 7,630 06/17/21
Glenn Gregory M President, R&D President, R&D Jun 17 Sell 191.31 8,127 1,554,776 2,811 06/17/21
Glenn Gregory M President, R&D President, R&D Apr 19 Option 61.73 10,531 650,079 7,630 04/19/21
MCMANUS MICHAEL A JR Director Director Mar 23 Sell 220.99 4,000 883,960 5,951 03/23/21
Trizzino John EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 09 Option 21.38 3,404 72,778 670 03/09/21
Trizzino John EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 09 Sell 163.31 3,211 524,388 287 03/09/21
Herrmann John A III EVP, Chief Legal Off.. EVP, Chief Legal Officer Feb 03 Option 26.71 15,022 401,238 15,297 02/03/21
Herrmann John A III EVP, Chief Legal Off.. EVP, Chief Legal Officer Feb 03 Sell 241.28 15,022 3,624,508 275 02/03/21
Trizzino John EVP, CMO and CBO EVP, CMO and CBO Jan 07 Option 23.25 13,756 319,827 1,436 01/07/21
Trizzino John EVP, CMO and CBO EVP, CMO and CBO Jan 07 Sell 114.35 17,913 2,048,352 287 01/07/21
Erck Stanley C President and CEO President and CEO Nov 18 Sell 90.33 52,316 4,725,704 20,495 11/18/20
Erck Stanley C President and CEO President and CEO Nov 18 Option 32.7 52,317 1,710,766 72,811 11/18/20
Trizzino John EVP, CBO and CFO EVP, CBO and CFO Oct 01 Sell 111.32 2,250 250,470 5,087 10/01/20
Erck Stanley C President and CEO President and CEO Oct 01 Sell 111.71 12,233 1,366,548 20,494 10/01/20
Herrmann John A III EVP, Chief Legal Off.. EVP, Chief Legal Officer Sep 30 Option 5.95 24,750 147,262 43,054 09/30/20
Herrmann John A III EVP, Chief Legal Off.. EVP, Chief Legal Officer Sep 30 Sell 110.91 42,779 4,744,618 275 09/30/20
Glenn Gregory M President, R&D President, R&D Sep 30 Option 5.95 25,000 148,750 46,510 09/30/20
Glenn Gregory M President, R&D President, R&D Sep 30 Sell 110.91 44,949 4,985,295 1,561 09/30/20
Trizzino John EVP, CBO and CFO EVP, CBO and CFO Sep 30 Option 5.95 29,600 176,120 53,008 09/30/20
Trizzino John EVP, CBO and CFO EVP, CBO and CFO Sep 30 Sell 110.86 43,321 4,802,567 7,337 09/30/20
Erck Stanley C President and CEO President and CEO Sep 30 Option 5.95 50,000 297,500 74,606 09/30/20
Erck Stanley C President and CEO President and CEO Sep 30 Sell 110.91 29,112 3,228,813 32,727 09/30/20